Moderna gains as Arbutus/ Genevant settlement removes major financial risk
Source: SeekingAlpha
2026-03-04 09:18:05 ET
More on Moderna, Arbutus Biopharma, etc.
- Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
- Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Moderna surges after hours on patent settlement with Arbutus and Genevant
- Pfizer-backed Priovant wins FDA priority review for lead asset
Read the full article on Seeking Alpha
For further details see:
Moderna gains as Arbutus/ Genevant settlement removes major financial risk
Arbutus Biopharma Corporation
NASDAQ: ABUS
ABUS Trading
1.38% G/L:
$4.79 Last:
1,215,636 Volume:
$4.72 Open:
ABUS Latest News
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
November 13, 2025 07:30:00 am
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 07, 2025 08:00:00 am
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
ABUS Stock Data
$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster
